69C.F Tvardi Therapeutics Inc.
- Market cap
- EUR 14.8M
- P/E
- -
- P/B
- 1.63x
- ROE
- -316.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 69C.F undervalued?
Graham numberThe Graham number of Tvardi Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tvardi Therapeutics Inc. fundamental analysis
No fundamental analysis for Tvardi Therapeutics Inc. yet.
Tvardi Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tvardi Therapeutics Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathi…
Full company profileTvardi Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tvardi Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -21.2M | -18.7M | -28.1M | -26.7M | -27.4M |
| EBITDA | -20.5M | -17.3M | -28.0M | -26.7M | -27.3M |
| Net Income | -20.5M | -17.3M | -29.4M | -18.2M | -26.5M |
| EPS | -2.20 | -1.85 | -3.14 | -1.94 | -2.83 |
| Balance Sheet | |||||
| Total Assets | 45.1M | 27.0M | 35.2M | 32.1M | 17.5M |
| Total Liabilities | 90.1M | 89.1M | 126M | 11.1M | 9.14M |
| Shareholders' Equity | -45.1M | -62.1M | -91.1M | 20.9M | 8.38M |
| Cash & Short-term Investments | 21.5M | 22.9M | 31.6M | 20.7M | 15.8M |
| Cash Flow | |||||
| Operating Cash Flow | -17.9M | -21.0M | -18.3M | -23.5M | -30.2M |
| Capital Expenditure | 50.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -17.9M | -21.0M | -18.3M | -23.5M | -30.2M |
| Ratios | |||||
| ROE | - | - | - | -87.0% | -316.4% |
| ROA | -45.6% | -64.2% | -83.5% | -56.8% | -151.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Tvardi Therapeutics Inc. dividends
Tvardi Therapeutics Inc. has not paid dividends in the last 4 fiscal years.
Who owns Tvardi Therapeutics Inc.
- Insiders 24.36%
- Institutions 16.77%
- Public & others 58.86%
- Shares outstanding 13.3M
- Free float 9.63M
Tvardi Therapeutics Inc. company profile
- Company name
- Tvardi Therapeutics Inc.
- Ticker
- 69C.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
- Phone
- 713 489 8654
- Website
- tvarditherapeutics.com
About Tvardi Therapeutics Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics Inc. management
9- Dr. Imran Alibhai Ph.D.CEO & Director · born 1976
- Mr. Dan Conn J.D., M.B.A.CFO & Corporate Secretary · born 1968
- Dr. John Kauh M.D.Chief Medical Officer · born 1974
- Mr. David J. Tweardy M.D.Co-Founder & Scientific Advisory Board Member
- Dr. Ronald A. DePinho M.D.Co-Founder & Chairman of Scientific Advisory Board · born 1955
- Dr. Michael T. Lewis Ph.D.Co-Founder & Scientific Advisory Board Member
- Dr. Jeffrey Larson DABT, Ph.D.Senior Vice President of R&D · born 1962
- Mr. Stephen O'Brien CPAVP of Finance & Corporate Controller
- Dr. Yixin Chen Ph.D.Vice President of CMC · born 1961